Results 181 to 190 of about 26,261 (211)

Glucagon-Like Peptide-1 Receptor Agonists and Cancer

JAMA Oncology
Mahyar, Etminan, Connor, Frey, Mohammad A, Mansournia   +2 more
openaire   +4 more sources

Possible Mechanisms Underlying the Effects of Glucagon-Like Peptide-1 Receptor Agonist on Cocaine Use Disorder

Frontiers in Pharmacology, 2022
Changliang Zhu, Wang Yezhong
exaly  

Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management

Current Pharmaceutical Design, 2021
Pantelis Zebekakis, Artemis Kyriakidou, Yiannis Vasilopoulos   +2 more
exaly  

Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study

Frontiers in Pharmacology, 2022
Wen Hsuan, Shu-I Wu, Ming-Chieh Tsai
exaly  

Glucagon-like peptide-1 receptor agonist attenuates diabetic neuropathic pain via inhibition of NOD-like receptor protein 3 inflammasome in brain microglia

Diabetes Research and Clinical Practice, 2022
Xiaoxia Liu, Yiming Li, Bin Lu
exaly  

Glucagon-Like Peptide-1 Receptor Agonists—How Safe Are They?

JAMA Internal Medicine, 2022
Shanzay, Haider, Kasia J, Lipska
openaire   +2 more sources

GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS

2020
COATES DAVID ANDREW, FIELDS TODD, HO JOSEPH DANIEL, QU FUCHENG   +3 more
openaire   +3 more sources

Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Provides Neuroprotection in Mice Transient Focal Cerebral Ischemia

Journal of Cerebral Blood Flow and Metabolism, 2011
Shinichiro Teramoto, Kenji Yatomi, Nobutaka Hattori   +2 more
exaly  

No pancreatic safety concern following glucagon‐like peptide‐1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials

Diabetes/Metabolism Research and Reviews, 2018
Jin Yang, Qing Tian, Tianpei Hong
exaly  

Glucagon-Like Peptide-1 Receptor Agonists and Osteoarthritis

New England Journal of Medicine
openaire   +2 more sources